Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

Pre-Market: $9.31 -0.04 (-0.43%) 8:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study

Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.

Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

Is (NVAX) Outperforming Other Medical Stocks This Year?

5 Biotech Stocks Up More Than 100% This Year So Far

Here we discuss five biotech companies recording impressive growth so far in 2020.

Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa

Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.

Company News for Aug 18, 2020

Companies In The News Are: DPZ, NVAX, JD, CRTX.

Company News for Aug 17, 2020

Companies in the news are: AMAT, MESO, NVAX, SKYS

Encompass Health's Buyout Spree on Track, PPE Costs High

Encompass Health (EHC) continues to benefit from buyouts and cash generating abilities. However, increased PPE utilization is worrisome.

Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government

Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.

FUJIFILM (FUJIY) Q1 Earnings Top Estimates, Revenues Drop Y/Y

FUJIFILM's (FUJIY) fiscal first-quarter results reflect coronavirus impact on the top line and operating income.

Neena Mishra headshot

Should You Invest in COVID Themed ETFs?

We highlight three new ETFs that seek to capitalize on coronavirus

Novavax's (NVAX) Earnings Beat in Q2, Sales Lag Estimates

Novavax's (NVAX) loss narrows for the second quarter of 2020 but revenues miss the mark.

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of 47.37% and -21.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics

The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics

Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?

Is (NVAX) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Sweta Killa headshot

Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Stock Market News for Aug 6, 2020

Wall Street closed higher on Wednesday supported by some developments regarding Congressional negotiations on a second round of fiscal stimulus.

Novavax (NVAX) Gains As Market Dips: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $146.62, marking a +0.87% move from the previous day.

Will Novavax (NVAX) Report Negative Q2 Earnings? What You Should Know

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Jaiswal, FRM headshot

Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain

Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.

Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings

Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.

Sanghamitra Saha headshot

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

What's in Store for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax